Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis

Current Opinion in Investigational Drugs

Volumn 8, Issue 5, 2007, Pages 423-428

  Monteleone, Giovanni ^a   Caprioli, Flavio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

12 SULFODEHYDROABIETIC ACID; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; PANITUMUMAB; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID;

CLINICAL TRIAL; CONSTIPATION; DEFECATION HABIT; DIARRHEA; DRUG WITHDRAWAL; EUROPE; HUMAN; JAPAN; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS; UNITED STATES;

ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-ULCER AGENTS; COLITIS, ULCERATIVE; DITERPENES, ABIETANE; ENEMA; HUMANS; TREATMENT OUTCOME;

EID: 34247884346     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 35027 Effects of the new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on duodenal alkaline secretion in rats. Onoda Y, Magaribuchi T, Tamaki H ARZNEIMITTEL-FORSCH 1990 40 5 576-578
2. 35028 Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric mucosal lesions induced by necrotizing agents and gastric mucosal defensive factors in rats. Onoda Y, Takido M, Magaribuchi T, Tamaki H JPN J PHARMACOL 1990 52 4 631-638
3. 163501 Tanabe Annual Report. Tanabe Seiyaku Co Ltd ANNUAL REPORT 1994 October 07
4. 194722 Gastrom Gran. Receives indication for gastritis. PHARMA JPN 1995 1481 6
5. 366841 Protective effect of ecabet sodium solution enema in experimental colitis models in rats. Kono T, Ohara K, Nomura M, Yoneda M, Ashida T, Kohgo Y, Kasai S GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 3029
6. 366855 Evaluation of the use of ecabet sodium enema in patient with refractory ulcerative colitis: Preliminary report. Nomura M, Kono T, Kasai S, Ashida T, Kohgo Y GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 3041
7. 417803 Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: An open-label study. Kono T, Nomura M, Kasai S, Kohgo Y AM J GASTROENTEROL 2001 96 3 793-797
8. 432595 Comparative tolerability of treatments for inflammatory bowel disease. Stein RB, Hanauer SB DRUG SAF 2000 23 5 429-448
9. 455014 Epidermal growth factor-related peptides and their receptors in human malignancies. Salomon DS, Brandt R, Ciardiello F, Normanno N CRIT REV ONCOL HEMATOL 1995 19 3 183-232
10. 459598 aaiPharma announces joint venture with Tanabe Seiyaku Co Ltd - JV will expand product pipeline to fuel organic growth. aaiPharma PRESS RELEASE (2002): July 30
11. 478682 R&D pipeline. Tanabe Seiyaku Co Ltd COMPANY WORLD WIDE WEB SITE 2002 November 07
12. 554411 R&D pipeline. Tanabe Seiyaku Co Ltd COMPANY WORLD WIDE WEB SITE 2004 July 23
13. 606306 Therapeutic effects of ecabet sodium, an antiulcer drug, on dextran sodium sulfate-induced ulcerative colitis in rats. Noto T, Yamada H, Inui T, Okuyama K, Watanable A, Kimura I, Nagasaki M DIG DIS SCI 2005 50 5 922-927
14. 606307 A case of radiation colitis improved with ecabet sodium enema. Kuriyama M, Kato J, Imagawa A, Hori S, Kawamoto H, Okada H, Shiratori Y GASTROENTEROL ENDOSC 2005 47 1 32-36
15. 606308 A successful treatment for cap polyposis by oral steroid administration and ecabet sodium enema, report of a case. Nakajima M, Yamada A, Makamura H, Nagase H, Sadamitsu D, Maekawa, Ogino H, Kodama N STOMACH INTEST 2002 37 5 735-740
16. 606309 A case of radiation colitis improved by enema therapy with ecabet sodium. Matsumoto M, Maruta M, Maeda K, Utsumi T, Sato Y, Takizawa K, Masumori K, Matsuoka H J JPN SOC COLOPROCTOL 2001 54 7 489-492
17. 667574 Tanabe Seiyaku company website. Tanabe Seiyaku Co Ltd COMPANY WORLD WIDE WEB SITE 2006 May 11
18. 729774 Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis. Iizuka M, Itou H, Konno S, Shirasaka T, Horie Y, Shindo K, Watanabe S GUT 2006 55 10 1523
19. 744336 Efficacy of ecabet sodium enema on steroid-resistant or steroiddependent ulcerative colitis. Itou H, Iizuka M, Horie Y, Konno S, Shindo K, Sato A, Watanabe S GASTROENTEROLOGY 2005 128 4 Suppl 2 A578
20. 770031 Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric secretion and experimental ulcers in rats. Onoda Y, Magaribuchi T, Tamaki H JPN J PHARMACOL 1989 51 1 65-73
21. 770032 Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS, 10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7- (1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). II. Distribution in the rat stomach. Ito Y, Sugawara Y, Takaiti O, Nakamura S J PHARMACOBIODYN 1991 14 9 547-554
22. 770036 Effects of ecabet sodium, a novel gastroprotective agent, on mucin metabolism in rat gastric mucosa. Ichikawa T, Ishihara K, Hayashida H, Hiruma H, Saigenji K, Hotta K DIG DIS SCI 2000 45 3 606-613
23. 770048 Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. I. Inactivation of enzyme protein. Ito Y, Nakamura S, Onoda Y, Sugawara Y, Takaiti O JPN J PHARMACOL 1993 62 2 169-174
24. 770067 Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium. Kinoshita M, Kume E, Tamaki H J PHARMACOL EXP THER 1995 275 1 494-501
25. 770076 Possible mechanism of increase in gastric mucosal PGE2 and PGI2 generation induced by ecabet sodium, a novel gastroprotective agent. Kinoshita M, Tamaki H DIG DIS SCI 1997 42 1 83-90
26. 770124 Inhibition of Helicobacter pylori-induced nuclear factor-κB activation and interleukin-8 gene expression by ecabet sodium in gastric epithelial cells. Kim JM, Kim JS, Jung HC, Oh YK, Kim N, Song IS HELICOBACTER 2003 8 5 542-553
27. 770130 Guidelines for the management of inflammatory bowel disease in adults. Carter MJ, Lobo AJ, Travis SP GUT 2004 53 Suppl 5 V1-V16
28. 770132 Mucin depletion in inflammatory bowel disease. McCormick DA, Horton LW, Mee AS J CLIN PATHOL 1990 43 2 143-146
29. 770133 The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, Ichikawa A et al J CLIN INVEST 2002 109 7 883-893
30. 770147 Ecabet sodium prevents the delay of wound repair in intestinal epithelial cells induced by hydrogen peroxide. Sasaki K, Iizuka M, Konno S, Shindo K, Sato A, Horie Y, Watanabe S J GASTROENTEROL 2005 40 5 474-482
31. 770154 Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Sharon P, Stenson WF GASTROENTEROLOGY 1984 86 3 453-460
32. 770155 Review article: Problematic proctitis and distal colitis. Gionchetti P, Rizzello F, Morselli C, Campieri M ALIMENT PHARMACOL THER 2004 20 Suppl 4 93-96
33. 770158 Putting rectal 5-aminosalicylic acid in its place: The role in distal ulcerative colitis. Marshall JK, Irvine EJ AM J GASTROENTEROL 2000 95 7 1628-1636
34. 770160 Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS NAT MED 2002 8 3 289-293
35. 770164 Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ N ENGL J MED 2003 349 4 350-357
36. 770214 Panitumumab in colon cancer: A review and summary of ongoing trials. Wainberg Z, Hecht JR EXPERT OPIN BIOL THER 2006 6 11 1229-1235
37. 770216 Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Ito Y, Shibata K, Hongo A, Kinoshita M EUR J PHARMACOL 1998 345 2 193-198
38. 770220 Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Shibata K, Ito Y, Hongo A, Yasoshima A, Endo T, Ohashi M ANTIMICROB AGENTS CHEMOTHER 1995 39 6 1295-1299
39. 770261 Mucins and inflammatory bowel disease. Shirazi T, Longman RJ, Corfield AP, Probert CS POSTGRAD MED J 2000 76 898 473-478
40. 774787 Munakata W, Liu Q, Shimoyama T, Sawaya M, Umeda T, Sugawara K: Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Luminescence (2003) 18(6):330-333
41. 774859 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: A randomized, controlled trial. Friedman LS, Richter JM, Kirkham SE, DeMonaco HJ, May RJ AM J GASTROENTEROL 1986 81 6 412-418
42. 774862 Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. Rachmilewitz D BR MED J 1989 298 6666 82-86
43. 776815 Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Kornbluth A, Sachar DB AM J GASTROENTEROL 2004 99 7 1371-1385